lifestyle.newsblaze.com

Author: Annovis Bio Inc.

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

April 9, 2026
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

April 2, 2026
Annovis Publishes Historical Review of Buntanetap in The Scientist

March 31, 2026
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson’s Disease Study

March 19, 2026
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

March 16, 2026
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

March 3, 2026
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

February 13, 2026